Adrian Frick, M.D.

M.D., PhD student @MedUni_Wien ; Resident @kim3_med , Gastro+Hepato Unit , interested in FMT, IBD, GI cancer, ep.barrier fct & ISCs; @EurFMT

[Adrian Frick, M.D. @aktibes]

@drkeithsiau https://t.co/gfpchHVtY1

[Gut Journal @Gut_BMJ]

#GUTOnline #GUTRecentAdvancesInClinicalPractice paper by @PinterMatthias et al entitled

"Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction" via

https://t.co/R3HKfrztqC

#HCC

[Keith Siau @drkeithsiau]

Today I learnt that there are 3 different types of hunger

📸: https://t.co/a1fLJl9Egh

[Beatriz Gros @Bealoquebea]

📢 Thrilled to share our latest study in @JCC_IBD

Tofacitinib vs vedolizumab as first-line advanced therapies in #UC

➡️ https://t.co/qn4IvPXjXX

#IBD
Grateful to work with this team ❤️@charlie_lees @PlevrisN @IBDNathan @claire_ohare_ @Gastro_GRJ @_Jake_15

[IMCrit @IM_Crit_]

I have to warn you that this is a long read. But it's fascinating. The story of an oncologist who built a kingdom in Montana. Until another physician looked at the data & said: "That doesn’t make any sense” (one of my favorite phrases, by the way...)

https://t.co/eS12lCwuZu

[Jens Walter @JensWalter15]

For somebody working on the gut #microbiome, the responses ("gross", "embarrassment", "pseudoscience", etc.) to this @Nature article on the treatment of C-section babies with their mother’s poo are quite sobering. So, I thought I would provide a perspective in the thread below.

[Kevin Whelan @ProfWhelan]

Studies showing how the #microbiome and #health response to #prebiotics and #probiotics vary and are influenced by background dietary intake

Paper @NatureMicrobiol 👉🏽 https://t.co/S3yg4CrbVI

[Mechanical Life Support @MLSCourse]

🏆UK champions heading to @EuroELSO in Milan 2025 looking like a dominant force.

[DrShahidaDin @ShahidaDin1]

Several stakeholders have advocated for minimising placebo controlled RCTs. We analysed the harms [Adverse Events,[AEs]] associated with placebo in inflammatory bowel diseases (IBD) RCTs. @alex_ford12399 @Bealoquebea @Jonathansegal85 @JonnyBlackwell @DrCJBlack @GastroRes_Leeds

[Antonio Caballero Mateos PhD @Dr_ACaballero_]

🗒️2024 ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment 💊

@Y_ECCO_IBD
 #IBD #MedEd #GITwitter #MedTwitter

1️⃣4️⃣ Statements and 6️⃣Practice points

1️⃣ 5-ASA is not recommended🚫for the induction or maintenance therapy in CD➡️consistent lack of evidence.

🧵👇

[WeersmaLab @WeersmaLab]

Exploring the previously reported gut #microbiome acetyltransferase genes involved in metabolism of 5-ASA in #ibd we could not replicate the original findings from @NatureMedicine in our Dutch 1000IBD cohort. More work needed. @GroMicrobiome
https://t.co/o5ckLJrj9J

[Ildiko ☕️ @IldikoMe]

I really hate to be the negative one but a dose of reality is needed. I think this is an overstatement intended to make people feel good. But the reality as a parent is simply not this. I will remind everyone again that we still don’t know what causes IBDs, or flares of disease, or how to reliably define whether these are different diseases or phenotypes. Despite the assertions in the linked Nature article, we actually have no idea, still, if IBDs are autoimmune. We have the same few drugs approved for pediatric IBD as two decades ago. Even with off-label use of newer drugs the best we can do is trial and error immunosuppression with a high failure rate. It’s a coin flip between optimal outcomes and SAEs, especially long-term. Surgery is still a mainstay. We have hit repeated dead ends with genetics and with biomarkers—at least nothing to date is of clinical utility beyond calprotectin. For years we have been hearing about being on the cusp of a major breakthrough. As much as we all want to feel valued for our work and celebrate a talk or a paper or a grant—and we should—we also need to remember why we’re still here decades on, and stop patting ourselves on the back until we have meaningfully answered the deep enduring questions. Parents feel like they are in a sinking boat and the community applauds itself for bailing out a cup of water.

[NEJM @NEJM]

Brief Report: Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease https://t.co/YzKRLvIUnZ

#Pediatrics

[Josh Farkas MD 💊 @PulmCrit]

when you admit a nonagenerian who weighs 45 kg, is on hemodialysis, is getting apixiban 5 mg BID, and needs an emergent invasive procedure:

[Maximilian_Baumgartner @GI_Baumgartner]

Our review about endoscopically visible mucosal #biofilms is out in @AGA_Gastro. We discuss pathophysiology, potential treatments and highlight knowledge gaps and open research questions

https://t.co/Udkvj0vj4H

@MedUni_Wien @univienna

[Intensive Care Medicine @yourICM]

Gut microbiome?? Organ implicated in both health & disease... What happens in critical illness?
🧫 intestinal microbiome in #ICU: dysbiosis as potential therapeutic target?
⛑️ protective/ecological restorative strategies
Free to read #FOAMcc on @yourICM
🔓 https://t.co/QWVjPAjMiF

[GutMicrobiota Health @GMFHx]

Johann Hammer acknowledges that intestinal dysbiosis but not SIBO is the potential cause of clinical symptoms

Current SIBO tests has lots of limitations and 48% of results are false positive due to rapid transit

#IBSDays2024

[James Lee @Dr_James_Lee]

There's been amazing coverage of our new paper @Nature https://t.co/qkrUksBYVW but I wanted to put together a walk-through (and make this accessible as possible). It's a bit long so get a cup of tea! The full version is open access so pls do have a read if you are interested...

[nature @Nature]

Nature research paper: A disease-associated gene desert directs macrophage inflammation through ETS2 https://t.co/axlOvslvMN

[Harry Sokol @h_sokol]

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications. ⁦@Gut_BMJ⁩ https://t.co/QWzKGSPjrI